Meta Layoffs for AI? ServiceNow Selloff Opportunity + HIMS After the Novo Deal

Welcome back to Episode 4 of Talkin’ Tickers — chaos weather, chaotic markets, same vibe. We kick it off with Meta and the Reuters layoff report: is Zuck heading toward Year of Efficiency 2.0 to fund AI capex? And bigger picture… when do layoffs go from “bullish” to “uh oh” for the consumer? Then we pivot to ServiceNow. Stock’s down hard, fundamentals look fine. We break down what NOW actually does, why “workflow + proprietary data” matters in an AI world, and why software has been getting sold first and questions asked later. Finally, we hit HIMS — the name you can’t criticize without getting jumped in the replies. We talk the Novo Nordisk deal, what it changes, what still needs to improve (subscriber growth), and why the risk/reward looks way more realistic now than it did at the highs. Disclaimer: All opinions expressed on this show are solely the opinions of the hosts’ and guests’ and do not reflect the opinions of Stocktwits, Inc. or its affiliates. The hosts are not SEC or FINRA registered advisors or professionals. The content of this show is for educational and entertainment purposes only. Please consult with your financial advisor before making any investment decision. Read the full terms & conditions here: https://stocktwits.com/about/legal/terms/ Chapter Timestamps (dash format) 00:00 - Episode 4 intro + Brad’s back home 00:30 - Meta layoff rumor to fund AI spend 01:18 - Brad’s take: capex priority + bottom line guardrail 02:54 - When do layoffs flip from good to bad? 03:53 - Unemployment becomes the key macro signal 06:21 - ServiceNow setup: Rule of 40 and hiring minimally 07:11 - What ServiceNow does + “AI watch tower” orchestration 08:46 - NOW stock down big despite strong quarter 09:14 - Valuation looks weird: trailing vs forward multiples 10:06 - Brad’s valuation approach: GAAP earnings + free cash flow 11:02 - Is NOW just caught in the software meltdown? 11:37 - Brad: sentiment-driven selling + proprietary data advantage 15:52 - “Stock broken, business isn’t” and the software bloodbath 19:30 - HIMS intro: cult stock + why it’s polarizing 20:06 - What HIMS does: direct-to-consumer healthcare marketplace 20:58 - The drawdown: $70 highs to the mid-20s 22:18 - Novo deal changes the setup + subscriber growth issue 25:49 - Peptides discussion + big pharma stranglehold risk 28:00 - How Brad values HIMS: plain GAAP net income 30:14 - Wrap + where to find Brad